25-hydroxyvitamin D response to cholecalciferol supplementation in hemodialysis

Laura A G Armas, Radha Andukuri, Janet Barger-Lux, Robert P. Heaney, Richard Lund

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Background and objectives Recent understanding of extrarenal production of calcitriol has led to the exploration of native vitamin D treatment in dialysis patients. This paper reports the pharmacokinetics of 25-hydroxyvitamin D response to 10,333 IU cholecalciferol given weekly in subjects on chronic dialysis. Design, setting, participants, & measurements This randomized, double-blind, placebo-controlled trial of 15 weeks of oral cholecalciferol in subjects with stage 5 CKD requiring maintenance hemodialysis was conducted from November of 2007 to March of 2010. The time course of serum 25-hydroxyvitamin D was measured over the course of treatment. Additionally, blood was drawn at baseline and last visit for calcium, phosphorus, calcitriol, and parathyroid hormone levels. Results The median (interquartile range) baseline 25-hydroxyvitamin D level was 13.3 (11.1-16.2) ng/ml for the treatment group and 15.2 (10.7-19.9) ng/ml for the placebo group. 25-hydroxyvitamin D steady state levels rose by 23.6 (19.2-29.9) ng/ml in the treatment group, and there was no change in the placebo group. Calcitriol levels also increased significantly in the treatment group. There were no significant changes in levels of calcium, albumin, phosphorus, and parathyroid hormone in either group. Conclusions Cholecalciferol (10,333 IU) given weekly in patients on chronic hemodialysis produces a steady state in 25-hydroxyvitamin D of approximately 24 ng/ml.

Original languageEnglish
Pages (from-to)1428-1434
Number of pages7
JournalClinical journal of the American Society of Nephrology : CJASN
Volume7
Issue number9
DOIs
StatePublished - Sep 1 2012

Fingerprint

Cholecalciferol
Renal Dialysis
Calcitriol
Placebos
Parathyroid Hormone
Phosphorus
Dialysis
Calcium
Therapeutics
Vitamin D
Albumins
Pharmacokinetics
Maintenance
25-hydroxyvitamin D
Serum

All Science Journal Classification (ASJC) codes

  • Nephrology
  • Transplantation
  • Epidemiology
  • Critical Care and Intensive Care Medicine

Cite this

25-hydroxyvitamin D response to cholecalciferol supplementation in hemodialysis. / Armas, Laura A G; Andukuri, Radha; Barger-Lux, Janet; Heaney, Robert P.; Lund, Richard.

In: Clinical journal of the American Society of Nephrology : CJASN, Vol. 7, No. 9, 01.09.2012, p. 1428-1434.

Research output: Contribution to journalArticle

Armas, Laura A G ; Andukuri, Radha ; Barger-Lux, Janet ; Heaney, Robert P. ; Lund, Richard. / 25-hydroxyvitamin D response to cholecalciferol supplementation in hemodialysis. In: Clinical journal of the American Society of Nephrology : CJASN. 2012 ; Vol. 7, No. 9. pp. 1428-1434.
@article{e232afa453324ab88518103578968d90,
title = "25-hydroxyvitamin D response to cholecalciferol supplementation in hemodialysis",
abstract = "Background and objectives Recent understanding of extrarenal production of calcitriol has led to the exploration of native vitamin D treatment in dialysis patients. This paper reports the pharmacokinetics of 25-hydroxyvitamin D response to 10,333 IU cholecalciferol given weekly in subjects on chronic dialysis. Design, setting, participants, & measurements This randomized, double-blind, placebo-controlled trial of 15 weeks of oral cholecalciferol in subjects with stage 5 CKD requiring maintenance hemodialysis was conducted from November of 2007 to March of 2010. The time course of serum 25-hydroxyvitamin D was measured over the course of treatment. Additionally, blood was drawn at baseline and last visit for calcium, phosphorus, calcitriol, and parathyroid hormone levels. Results The median (interquartile range) baseline 25-hydroxyvitamin D level was 13.3 (11.1-16.2) ng/ml for the treatment group and 15.2 (10.7-19.9) ng/ml for the placebo group. 25-hydroxyvitamin D steady state levels rose by 23.6 (19.2-29.9) ng/ml in the treatment group, and there was no change in the placebo group. Calcitriol levels also increased significantly in the treatment group. There were no significant changes in levels of calcium, albumin, phosphorus, and parathyroid hormone in either group. Conclusions Cholecalciferol (10,333 IU) given weekly in patients on chronic hemodialysis produces a steady state in 25-hydroxyvitamin D of approximately 24 ng/ml.",
author = "Armas, {Laura A G} and Radha Andukuri and Janet Barger-Lux and Heaney, {Robert P.} and Richard Lund",
year = "2012",
month = "9",
day = "1",
doi = "10.2215/CJN.12761211",
language = "English",
volume = "7",
pages = "1428--1434",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "9",

}

TY - JOUR

T1 - 25-hydroxyvitamin D response to cholecalciferol supplementation in hemodialysis

AU - Armas, Laura A G

AU - Andukuri, Radha

AU - Barger-Lux, Janet

AU - Heaney, Robert P.

AU - Lund, Richard

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Background and objectives Recent understanding of extrarenal production of calcitriol has led to the exploration of native vitamin D treatment in dialysis patients. This paper reports the pharmacokinetics of 25-hydroxyvitamin D response to 10,333 IU cholecalciferol given weekly in subjects on chronic dialysis. Design, setting, participants, & measurements This randomized, double-blind, placebo-controlled trial of 15 weeks of oral cholecalciferol in subjects with stage 5 CKD requiring maintenance hemodialysis was conducted from November of 2007 to March of 2010. The time course of serum 25-hydroxyvitamin D was measured over the course of treatment. Additionally, blood was drawn at baseline and last visit for calcium, phosphorus, calcitriol, and parathyroid hormone levels. Results The median (interquartile range) baseline 25-hydroxyvitamin D level was 13.3 (11.1-16.2) ng/ml for the treatment group and 15.2 (10.7-19.9) ng/ml for the placebo group. 25-hydroxyvitamin D steady state levels rose by 23.6 (19.2-29.9) ng/ml in the treatment group, and there was no change in the placebo group. Calcitriol levels also increased significantly in the treatment group. There were no significant changes in levels of calcium, albumin, phosphorus, and parathyroid hormone in either group. Conclusions Cholecalciferol (10,333 IU) given weekly in patients on chronic hemodialysis produces a steady state in 25-hydroxyvitamin D of approximately 24 ng/ml.

AB - Background and objectives Recent understanding of extrarenal production of calcitriol has led to the exploration of native vitamin D treatment in dialysis patients. This paper reports the pharmacokinetics of 25-hydroxyvitamin D response to 10,333 IU cholecalciferol given weekly in subjects on chronic dialysis. Design, setting, participants, & measurements This randomized, double-blind, placebo-controlled trial of 15 weeks of oral cholecalciferol in subjects with stage 5 CKD requiring maintenance hemodialysis was conducted from November of 2007 to March of 2010. The time course of serum 25-hydroxyvitamin D was measured over the course of treatment. Additionally, blood was drawn at baseline and last visit for calcium, phosphorus, calcitriol, and parathyroid hormone levels. Results The median (interquartile range) baseline 25-hydroxyvitamin D level was 13.3 (11.1-16.2) ng/ml for the treatment group and 15.2 (10.7-19.9) ng/ml for the placebo group. 25-hydroxyvitamin D steady state levels rose by 23.6 (19.2-29.9) ng/ml in the treatment group, and there was no change in the placebo group. Calcitriol levels also increased significantly in the treatment group. There were no significant changes in levels of calcium, albumin, phosphorus, and parathyroid hormone in either group. Conclusions Cholecalciferol (10,333 IU) given weekly in patients on chronic hemodialysis produces a steady state in 25-hydroxyvitamin D of approximately 24 ng/ml.

UR - http://www.scopus.com/inward/record.url?scp=84866111565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866111565&partnerID=8YFLogxK

U2 - 10.2215/CJN.12761211

DO - 10.2215/CJN.12761211

M3 - Article

VL - 7

SP - 1428

EP - 1434

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 9

ER -